Monitor for updates on the strategic review process and any potential partnerships or transactions. The FDA's requirement for a randomized controlled trial presents significant challenges that could impact the development path and valuation of PBFT02.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 20 $6.25entry
- T+1 · 7mo ago −1.12%α −0.47% · $6.18
- T+5 · 7mo ago −8.64%α −9.55% · $5.71
- T+20 · 6mo ago −18.08%α −22.28% · $5.12
- T+60 · 4mo ago −21.44%α −28.22% · $4.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Passage Bio disclosed updated interim data from its Phase 1/2 upliFT-D trial for PBFT02, showing reduced brain atrophy and stabilized plasma neurofilament levels in FTD-GRN patients. The FDA indicated a randomized controlled trial is required for registration, leading the company to evaluate strategic alternatives to maximize shareholder value.
Key Facts
- PBFT02-treated patients with CDR score 1 showed 64% reduction in whole brain atrophy and 54% reduction in frontotemporal cortex atrophy compared to natural history
- Plasma NfL levels among PBFT02-treated patients showed average reduction of 1.0 pg/mL at 12 months
- FDA indicated a randomized controlled registrational study design is required for PBFT02 in FTD-GRN indication
- Company has initiated a review of strategic alternatives including merger, acquisition, or sale of assets
- Cash runway expected through 1Q 2027
Financial Impact
No direct financial impact disclosed, but strategic review could lead to significant changes in company direction or valuation
Risk Factors
- FDA's requirement for randomized controlled trial presents ethical, logistical, and financial challenges
- Strategic review may not result in any transaction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-045219 |
| Document: tm2612152d1_8k.htm | 0001104659-26-045219 |
| Document: tm2612152d1_ex99-1.htm | 0001104659-26-045219 |
| Document: 0001104659-26-045219-index-headers.html | 0001104659-26-045219 |
| Document: 0001104659-26-045219-index.html | 0001104659-26-045219 |
| Document: 0001104659-26-045219.txt | 0001104659-26-045219 |
Track record
15 reports on PASG
2 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
- Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
- Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
- Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
- Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
- Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
- Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers